Lupin gets USFDA nod to market generic skin treatment medication
New Jersey-based Novel Laboratories Inc has received the approval from the US Food and Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, Lupin said in a statement.
Lupin on Wednesday said its American subsidiary has received approval from the US health regulator to market a generic product used for treatment of skin issues.
New Jersey-based Novel Laboratories Inc has received approval from the US Food and Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, Lupin said in a statement.
The product is the generic version of Hill Dermaceuticals Inc's Derma
New Jersey-based Novel Laboratories Inc has received approval from the US Food and Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, Lupin said in a statement.
The product is the generic version of Hill Dermaceuticals Inc's Derm-Smoothe/FS Topical Oil.
Lupin said the product will be manufactured at its Somerset facility in the US.
As per the IQVIA MAT March 2023 data, Fluocinolone Acetonide Topical Oil had estimated annual sales of USD 9 million in the US.
Lupin shares were trading 0.67 percent down at Rs 981.65 apiece on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Liquor stock under Rs 300: Can this smallcap scrip double your money in 1-2 years? Check targets by Anil Singhvi
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
12:46 PM IST